Analysis of Plasma Metabolic Profile on Ganglion Cell–Inner Plexiform Layer Thickness With Mortality and Common Diseases
Authors' conclusion
In this prospective study of multinational participants, GCIPLT-associated metabolites demonstrated the potential to inform mortality and morbidity risks. Incorporating information on these profiles may facilitate individualized risk stratification for these health outcomes.
Study context
- Population
- UK Biobank participants enrolled 2006–2010, community-based; 54.5% women, mean (SD) age 56.7 (8.1) years; validation in Guangzhou Diabetes Eye Study (GDES)UK Biobank
- Participants
- 93,838 participants
- Exposure
- Clinical indicators plus ganglion cell-inner plexiform layer thickness (GCIPLT) metabolic profiles vs clinical indicators only
- Outcome
- GCIPLT metabolic profiles from circulating plasma metabolites; their associations with mortality and morbidity of 6 common diseases, with incremental discriminative value and clinical utility
- Follow-up
- Mean (SD) 12.3 (0.8) years
Methodological detailsexternal validation cohort (GDES)
- External validation cohort (GDES)
Main finding
As reported in the abstract
Metabolic metrics associated with GCIPLT
Metabolic metrics examined
249
Independently associated with GCIPLT
37
Positive associations
8
Negative associations
29
Observational data: associations, not effects.
Further findings
C statistic
| Outcome | Clinical indicators only | P value |
|---|---|---|
| Discrimination of T2D (C statistic)Metabolic profiles + clinical indicators vs Clinical indicators only | 0.862 (95% CI 0.852–0.872) | P < 0.001 |
| Discrimination of MI (C statistic)Metabolic profiles + clinical indicators vs Clinical indicators only | 0.792 (95% CI 0.775–0.808) | P < 0.001 |
| Discrimination of HF (C statistic)Metabolic profiles + clinical indicators vs Clinical indicators only | 0.803 (95% CI 0.786–0.820) | P < 0.001 |
| Discrimination of stroke (C statistic)Metabolic profiles + clinical indicators vs Clinical indicators only | 0.739 (95% CI 0.714–0.764) | P < 0.001 |
| Discrimination of all-cause mortality (C statistic)Metabolic profiles + clinical indicators vs Clinical indicators only | 0.747 (95% CI 0.734–0.760) | P < 0.001 |
| Discrimination of CVD mortality (C statistic)Metabolic profiles + clinical indicators vs Clinical indicators only | 0.790 (95% CI 0.767–0.812) | P < 0.001 |
- Discrimination of T2D (C statistic): Clinical indicators only C statistic 0.803 (95% CI 0.792–0.814)
- Discrimination of MI (C statistic): Clinical indicators only C statistic 0.768 (95% CI 0.751–0.786)
- Discrimination of HF (C statistic): Clinical indicators only C statistic 0.790 (95% CI 0.773–0.807)
- Discrimination of stroke (C statistic): Clinical indicators only C statistic 0.719 (95% CI 0.693–0.745)
- Discrimination of all-cause mortality (C statistic): Clinical indicators only C statistic 0.724 (95% CI 0.711–0.738)
- Discrimination of CVD mortality (C statistic): Clinical indicators only C statistic 0.763 (95% CI 0.739–0.788)
Validation in GDES cohort
- Potential of GCIPLT metabolic profiles for CVD risk stratification confirmed in GDES using a different metabolomic approach
Original publication
Analysis of Plasma Metabolic Profile on Ganglion Cell–Inner Plexiform Layer Thickness With Mortality and Common Diseases. JAMA Netw Open. Published 1 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →